Meet our leadership team.
Meet our board of directors.
Have a question? Let’s chat
Fill out the form below and one of our staff will be in touch.
Chief Executive Officer
Larry has more than 35 years of executive leadership and operations experience from the therapeutic, medical device and biotechnology industries, with an extensive focus on business and product development and commercialization at both large-cap and early-stage medical device companies.
Most recently, Larry was President, Chief Executive Officer and Director of Flowonix, Inc., a privately held company marketing implantable drug-delivery systems for the management of pain and spasticity. Prior to that, he was President, Chief Executive Officer and Director of Cardiox Corporation, a privately held company that developed and marketed drug-device combination products for the structural heart and liver diagnostics markets. He also has served as President, Chief Executive Officer and Chairman of the board of Vioptix Inc., a privately held company in the tissue oximetry field, President, Chief Executive Officer, and Director of Curon Medical, Inc., a public company marketing products for the treatment of gastrointestinal disorders, and President, Chief Executive Officer and Director of Response Genetics, Inc., an applied genomics start-up firm providing gene expression services in the oncology market.
His earlier career spanned 18 years at United States Surgical Corporation (USSC), a leading manufacturer of innovative wound closure and advanced surgical products, serving in roles of increasing responsibility in Sales, Marketing, and General Management. His career at USSC culminated in his serving as President and Chief Operating Officer of USSC from 1998 through 2000.
Larry was awarded a Bachelor of Arts degree from Eastern Illinois University and is an inventor on several U.S. patents. He has served as a member of the board of several international medical societies and foundations, including the MITAC Board for the commercialization of NASA technology via partnerships with the medical industry.
Ann Cotter, CPA
Chief Financial Officer
Ann has primary responsibility for planning, implementation, and management of Zomedica’s finance activities, including business planning, budgeting, forecasting, and negotiations. She served as the Company’s Vice President of Finance from August 2018 until October 2020, when she was promoted to her current role.
Throughout her career, Ann has held various consulting, controllership, and Chief Financial Officer roles for both private and publicly held companies and has public accounting experience in both audit and tax services. She served as Chief Financial Officer of American Fence Company, a fence rental, installation, and manufacturing company, from April 2018 through August 2018. She has also served as Corporate Controller of ProMotion Technology Group, a digital solutions provider, from September 2014 through August 2017. Ann holds a Master of Taxation from Capital University Law School and a Bachelor of Arts in Economics and Spanish from Capital University. She is a Certified Public Accountant, licensed in Ohio since 1996.
Executive Vice President, Operations
Tony recently joined Zomedica in January 2022. Prior to joining Zomedica, he was a principal founder of BGA Mfg. Services LLC, a manufacturing and operations consulting organization. Tony was COO of Cardiox Corporation from 2012 through 2016, a privately held company that developed, manufactured, and marketed drug-device combination products for the structural heart and liver markets. Tony has more than 30 years of operations leadership experience in the medical device and pharmaceutical industries.
Before joining Cardiox in 2012, Tony served as VP of Manufacturing for Devicor Medical Products, the parent corporation of Mammotome, a global company dedicated to acquiring and growing healthcare companies which subsequently acquired Neoprobe, a public company, where he served as Vice President, of Manufacturing Operations.
Prior to Neoprobe, Tony served as Vice President, Manufacturing Operations of Enpath Medical, from 2002 to 2004 which acquired Biomec Cardiovascular, Inc.
From 1998 through 2001, Tony led the manufacturing efforts at Astro Instrumentation, a medical device contract manufacturer. He was part of the leadership of the company from its initial start-up in 1998. Prior to Astro, he spent 10 years at Ciba-Corning Diagnostics (now Bayer), in various managerial capacities including Operations Manager, Materials Manager, Purchasing Manager, and Production Supervisor. Before that, he was employed by Bailey Controls and held various positions increasing in responsibility in purchasing and industrial engineering. Mr. Blair started his career at Fisher Body a division of General Motors in production supervision.
He holds a Bachelors’s degree in Business Administration from Cleveland State University.
Greg Blair, MBA
Vice President of Business Development & Strategic Planning
Greg is a dynamic life sciences leader with experience across business development, commercial, product development, and finance roles. He is responsible for building and executing an external innovation strategy to maximize shareholder value.
Greg’s focus is on creating value-added partnerships and acquiring differentiated technology that helps Zomedica’s customers thrive in practice and supports their mission to enhance the veterinary care experience for pets and pet parents.
Greg joined Zomedica from Elanco Animal Health, where he was known for his collaborative approach to creating strategic alliances that built trust and confidence with partners across the industry. While at Elanco, Greg delivered multiple successful transactions, including acquisitions, divestitures, strategic alliances, equity investments, and licensing transactions.
He has dedicated his career to leading teams that deliver innovative solutions for customers with companies such as Johnson and Johnson, Intuitive Surgical and Enteromedics. Greg’s passion for innovation and pursuit of technologies that solve unmet needs, improve clinicians’ practices and enrich patient lives led him to launch numerous innovative products throughout his career.
Outside of work, Greg enjoys spending quality time with his wife and young son, as well as their Beauceron, Poscoe. He is a private pilot, and the family enjoys taking trips around the eastern US to anywhere with a beach and warm weather.
Vice President and General Manager
Adrian joined the Zomedica leadership team in October 2021 when the company he founded in 2009, Pulse Veterinary Technologies, LLC (“PulseVet”) was acquired. He brings over 30 years of human and veterinary healthcare and biotechnology sales, marketing, and executive leadership experience to the organization.
Prior to PulseVet, Adrian was Vice-President of Sales and Marketing with Sanuwave, where he devoted his energy and resources to developing and commercializing shock wave technology. While at Sanuwave he took over the veterinary division, allowing him to combine his training and background with his lifelong passion for animals. In 2009 the veterinary division of Sanuwave split to form PulseVet. As Director of Global Marketing with CryoLife, he launched BioGlue ® Surgical Adhesive in 2001. BioGlue is a life-saving product now recognized as the leading surgical adhesive in worldwide clinical use for indications in cardiovascular, neurological, and soft tissue surgeries.
Prior to starting his healthcare career, Adrian served in the US Navy as a nuclear-trained submarine officer, where he was awarded a Navy Achievement Medal and a Navy Commendation Medal for his service aboard 2 submarines, USS Flying Fish (SSN673), USS Scranton (SSN756), and as a Watch Officer at ComSubLant.
Adrian holds a BS degree in Engineering Science from Vanderbilt University, which he attended on a Navy ROTC scholarship.
In his free time, Adrian enjoys playing guitar, fitness/outdoor activities, and spending time with his wife, Rhonda, four daughters, two granddaughters, two dogs, and a cat.
Nicole Westfall, MBA
Vice President of Marketing
Nicole brings more than 25 years of experience in marketing, sales, and communications covering the gamut of marketing arenas from corporate communications to product management to event planning to media. Passionate about animal health, she has spent the last decade working with various manufacturers to spread the word about their products and services.
Most recently, Nicole was the Senior Director of Sales and Marketing for Assisi Animal Health, a privately held company specializing in TPEMF medical devices to help pets live better pain and anxiety-free lives. She has, also, served as Associate Director of Marketing for PRN Pharmacal with a focus on marketing their flagship product, PROIN, along with their line of nutraceuticals for inflammation and pain.
Nicole spent her earlier career in various forms of the marketing and media realm. She successfully ran her own marketing/advertising agency for 15 years but also spent time on the media side of the business. She has been published in over 100 publications as well as worked in various positions in television and radio.
Ms. Westfall holds a Bachelor’s Degree in Communications from Baylor University and an MBA in International Business from the University of Texas, Arlington.
Vice President of Human Resources
Kristin joined the Company on January 24, 2022, as its Vice President, Human Resources. Kristin holds a B.S. in Leadership Studies and a M.S. in Human Resources Administration from Central Michigan University and brings 30 years of HR experience to Zomedica. Her career includes HR roles in banking, consulting, life sciences, and healthcare.
Most recently she was VP of Human Resources for Nexcare Wellbridge Senior Living, a large skilled nursing organization in Michigan, and before that was Director of HR, North America, for Enzo Life Sciences, with locations in Michigan and New York. Kristin’s breadth of experience across all facets of Human Resources, and success in building HR systems and programs, will be focused on the goal of developing a best-in-class HR experience for Zomedica and all acquired entities.
Evan St. Peter, MBA
Vice President of Technology Innovation
Evan joined Zomedica in September of 2018 to lead the development of a cloud-based data platform to capture data from Zomedica’s diagnostic devices. This platform is known as MyZomedicaTM today. He now leads the company’s technology innovation for both Zomedica’s customer-facing digital technology as well as Zomedica’s internal technology needs.
Prior to joining Zomedica, Evan was part of the Connected Care team within Stryker’s Medical and Surgical Division, where he helped lead the delivery of Stryker’s customer-facing IoT and machine learning application called Smart Equipment Management. During his time at Stryker, he was responsible for leading Agile application development across onshore and offshore development teams as well as the statistical validation of supervised machine learning models to identify surgical devices that would benefit from preventative maintenance. In addition to his time at Stryker, Evan brings operations and enterprise IT experience from his time at MPI Research, where he held roles of increasing responsibility throughout his career there.
Evan holds a Bachelor of Science in Biology from Northern Michigan University and a Master of Business Administration from Western Michigan University. He is the father of two boys. He and his wife enjoy family camping and home DIY, and he is an avid cyclist.
Ashley Wood, PhD
Senior Director of Research and Development
Ashley joined Zomedica in 2019 to facilitate the development of BAW technology for use in veterinary medicine. She now leads the company’s research and development activities. Ashley’s expertise is in the areas of molecular biology, cell biology, imaging techniques, and biochemistry.
Prior to her current role, Ashley was part of the R&D group at Swift Biosciences, where she was responsible for creating market viable products as the lead scientist in the advancement of next-generation sequencing assays. Her responsibilities included assay development, bioinformatic analysis, and transfer to manufacturing.
Ashley also served as a research assistant professor and completed a postdoctoral research fellowship (awarded by the American Cancer Society) in the Cell & Molecular Biology department at Northwestern University’s Feinberg School of Medicine. She has co-authored several papers that have appeared in industry-prominent journals.
Ashley graduated with honors from Duke University with a degree in biochemistry and earned a Ph.D. in molecular biology from Johns Hopkins University. She is the mother of two young boys, and when she’s not transporting them to hockey, baseball, or other activities, she enjoys cooking, running, and spending time outdoors.
Karen DeHaan-Fullerton, J.D.
General Counsel and Corporate Secretary
As General Counsel, Karen has responsibility for all Zomedica legal functions for building strategy across regulatory, risk, and compliance functions and helping to drive the company from a legal perspective.
Karen joined Zomedica in June 2022 and brings more than 24 years of diverse legal expertise to Zomedica. After graduating cum laude from the University of Louisville – Louis D. Brandeis School of Law, she practiced with the firm Goldberg & Simpson in Louisville before moving to Indianapolis to practice with Sommer Barnard (later Taft, Stettinus, and Hollister) as an M&A partner. In 2007, she joined Zimmer, Inc. serving in roles of increasing responsibility as Division General Counsel, Assistant General Counsel, Global Businesses and Americas, and Division General Counsel, Zimmer Biomet. In 2016 she joined Elanco Animal health negotiating and drafting business development agreements for asset purchases, divestitures, licenses, collaborations, co-promotions, and distribution opportunities, as well as providing legal support to the North America commercial and companion animal business units, and the corporate secretary’s office. Most recently, Karen was the Senior Transaction Attorney, Associate General Counsel for Exactech Inc.
With over 30 years of experience in the specialty pharmacy industry, Jeff Rowe most recently served as Executive Vice President and board member of Diplomat Inc., the largest independent specialty pharmacy company in the United States. During his tenure with Diplomat, the company grew from a single location with less than US$5 million in revenue, to 16 locations and US$3 billion in sales, and became publicly traded on the New York Stock Exchange. Prior to that, Jeff owned two successful community pharmacies in Genesee County, Michigan.
An authority in pharmaceutical operations, Jeff offers critical insights into fundamental business strategies involving accreditation, contracting, cybersecurity, and regulation, combined with expertise in compounding and integrative medicine. He is uniquely qualified to identify process improvements and efficiencies while maintaining compliance and quality standards, for increased revenue, profitability, and customer satisfaction. Jeff holds a Bachelor of Pharmacy degree from Ferris State University and has completed many health-related credential courses.
Mr. Cohen joined Zomedica in June of 2020 following successfully serving as President and Chief Executive Officer at a series of early-stage medical device and biotechnology companies. Prior to his 20 years in the CEO position, he was a member of senior management at large multinationals including St. Jude Medical, Inc., Sulzermedica, and Pfizer Inc.
Johnny D. Powers, PhD
Dr. Powers has more than 30 years of experience leading business strategy, operations, sales and marketing, and product development in the human and pet medical diagnostics markets. Notably, he held executive roles at animal health industry leader IDEXX Laboratories, Inc. (IDEXX), where, prior to his retirement, he served as executive vice president responsible for business performance, product innovation, and commercial effectiveness across multiple point-of-care and reference laboratory businesses. Currently, Powers is the president and founder of JD Powers Consulting Group, which provides strategic and executive advisory services in the healthcare industry. Dr. Powers holds a bachelor’s degree in chemistry from Wake Forest University, an M.S. in chemical engineering from Clemson University, an M.B.A. from the Duke University Fuqua School of Business, and a Ph.D. in biochemical engineering from North Carolina State University.
Rodney J. Williams
With over 20 years of medical technology and related healthcare experience, Rodney (Rod) Williams has demonstrated incredible agility and success in leading both large and small-cap companies through growth cycles, while strengthening their product portfolio and boosting commercial planning competencies. He is currently the Global Vice President of Portfolio and Services with Align Technology, Inc., which designs and manufactures products for dental professionals, including the Invisalign® system. Prior to Align Technology, he was an entrepreneur-in-residence with the private equity investment firm PTV Healthcare Capital and before that was president and CEO of Heart Rhythm Society Consulting Services. He also served in senior executive positions with St. Jude Medical, GE Healthcare, Johnson and Johnson, and Bausch & Lomb.
Rod earned both his MBA and Bachelor of Science degrees from the University of Southern California (USC) and attended the General Management Executive Leadership Program at The Wharton School of Business. While at USC, on a football scholarship, he gained NCAA Academic All-American honors and numerous academic awards as the TOP student-athlete. Rod was drafted into the National Football League in 1985.
Outside his work at Cambridge, Mr. MacLeod is the National Chair of the Canadian Cystic Fibrosis Treatment Society (CCFTS). The Society’s purpose is to advocate across sectors (government, charitable, insurance, and pharma) for access to innovative life-sustaining medication.
Additional corporate involvement includes sitting as Independent Director of Body and Mind (BAMM), a Nevada based Cannabis company listed on the CSX, serving as director of Pascal Financial Inc., a FINTECH company that provides a software solution for investment advisors and portfolio managers, and his commitment as corporate advisor to Citzn Inc. a social media start-up company.
Mr. Whelan presently is the Chief Executive Officer of Encore Rehabilitation Services, a provider of outcome-driven therapy services and associated compliance and revenue cycle support services. He also previously served as the Company’s CFO from 2017 to 2018.
From 2019 to 2020, Mr. Whelan served as CFO of Smile America Partners, and from 2018 to 2019 as CFO of Bedrock Manufacturing, LLC. He served from 2010 to 2016 as CFO, secretary, treasurer, and a director of Diplomat, Inc. (NYSE: DPLO), a then publicly-traded specialty pharmacy, where he was responsible for finance, external reporting, and investor relations, strategy, and M&A.
Mr. Whelan served from 2007 to 2010 as CFO of InfuSystem Holdings Inc., a publicly-traded health care services company. Prior to his various healthcare executive roles, Mr. Whelan held senior finance positions with Ford Motor Company from 1996 through 2007, including serving as accounting director for Automotive Components Holdings, LLC, a then Ford subsidiary.
Mr. Whelan began his career with Deloitte in 1994, serving a diverse set of audit clients in the firm’s Detroit office, and earned his CPA license while with the firm. He holds Bachelor of Business Administration and Master of Accounting degrees, both from the University of Michigan’s Ross School of Business. Mr. Whelan also presently serves (since 2019) on the Board of Directors of OptioRx, a specialty pharmacy company.